D-Attachment-PURCHASE DESCRIPTION Modified human mRNAs Transcripts.pdf

PDF 669 KB Posted

Attached to
Modified Human mRNA Transcripts
Solicitation number
75N95022Q00352
Issued by

View the file

Other files

File Type Posted
D-Attachment-FAR_52.204-24 (Nov 2021).pdf PDF
D-Attachment-FAR 52.212-5 (May 2022).pdf PDF
D-Attachment-FAR 52.212-4 Addendum.pdf PDF
D-Attachment-Invoicing Instructions Without IPP 4-21-22.pdf PDF
D-Attachment-FAR_52.204-26 (Oct 2020).pdf PDF

On GovTribe

Work with this file

  • Download the original file
  • Contacts named in this file
  • Similar government files
  • Ask GovTribe AI about this file
Try for free Login

Text version

The file's text, extracted by GovTribe without its formatting.

Version 11-30-2016-1 FAR Part 11—Describing Agency Needs

PURCHASE DESCRIPTION

1. Statement of Need and Purpose: The National Institute on Aging (NIA) is looking to acquire modified human mRNA transcripts to perform non-integrated reprogramming of human fibroblasts.

2. Background Information and Objective: Reprogramming aged animals and cells is a new technology in the aging field. Transient expression of nuclear reprogramming factors via mRNA transfection is a powerful method because of its safety and convenience in usage. In a typical successful transfection, the mRNA is usually modified to avoid innate immune stimulation in the host cells.

3. Generic Name of Product:

Modified human EZH2 mRNA Transcript Modified human OCT3/4 mRNA Transcript Modified human SOX2 mRNA Transcript Modified human KLF4 mRNA Transcript Modified human cMYC mRNA Transcript Modified human LIN28A mRNA Transcript Modified human NANOG mRNA Transcript Modified human EGFP mRNA Transcript Modified human E2F1 mRNA Transcript

4. Purchase Description:

Modified human EZH2, OCT3/4, SOX2, KLF4, cMYC, LIN28A, NANOG, E2F1 and EGFP mRNAs. Each mRNA is 1mg size.

5. Salient characteristics:

The modified mRNAs shall use proprietary CleanCap AG technology, a co-transcriptional capping strategy to add a Cap1 structure that significantly improves mRNA stability and bioavailability.

6. Quantity:

Modified human EZH2 mRNA Transcript (QTY=1mg/vial) Modified human OCT3/4 mRNA Transcript (QTY=1mg/vial) Modified human SOX2 mRNA Transcript (QTY=1mg/vial) Modified human KLF4 mRNA Transcript (QTY=1mg/vial) Modified human cMYC mRNA Transcript (QTY=1mg/vial) Modified human LIN28A mRNA Transcript (QTY=1mg/vial) Modified human NANOG mRNA Transcript (QTY=1mg/vial) Modified human EGFP mRNA Transcript (QTY=1mg/vial) Modified human E2F1 mRNA Transcript (QTY=1mg/vial)

7. Delivery Date: Within 60 days ARO

Version 11-30-2016-1 FAR Part 11—Describing Agency Needs

8. Period of Performance: N/A

9. Option(s): N/A

File details come from the government source that posted it. Updated .